Rotigotine: In Parkinson's Disease

CNS Drugs

Volumn 19, Issue 11, 2005, Pages 973-981

  Reynolds, Neil A ^a   Wellington, Keri ^a   Easthope, Stephanie E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; ROTIGOTINE; SELEGILINE;

CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; HUMAN; INSOMNIA; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SIDE EFFECT; SLOW DRUG RELEASE; SOMNOLENCE; TACHYCARDIA; TRANSDERMAL PATCH;

DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 27644476746     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200519110-00006     Document Type: Review

References (29)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004 May 29; 363 (9423): 1783-93
2. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurology 2004 May; 3 (5): 309-16
3. Chan KL, Jagait P, Tugwell C. Parkinson's disease: current and future aspects of drug treatment. Hospital Pharmacist 2004; 11 (1): 18-22
4. Stiasny-Kolster K, Kohnen R, Schollmayer E, et al. and The Rotigotine SP 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004; 19 (12): 1432-8
5. Stiasny-Kolster K, Garcia-Borreguero D, Saletu B, et al. Rotigotine in the treatment of moderate to severe idiopathic restless legs syndrome - a double-blind placebo-controlled multicenter dose-finding study [abstract no. P1242 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
6. Schwarz Pharma. Current development projects: Parkinson's disease [online]. Available from URL: http://www.schwarzpharma.com [Accessed 2005 Oct 4]
7. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005 Jul 26; 65 (2 Suppl. 1): S3-5
8. 2 agonist in the treatment of Parkinsonism. Mov Disord 1998 Sep; 13 (5): 768-74
9. 2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994 Mar; 9 (2): 147-54
10. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Invest Drugs 2003 Aug; 12 (8): 1335-52
11. Chase TN, Verhagen Metman L, Bravi D, et al. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease. Clin Neuropharmacol 1995; 18 Suppl. 1: S207-15
12. Kehr J, Scheller DKA. Continuous delivery of rotigotine leads to continuous dopamine receptor stimulation in a rat model [abstract no. P1285 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
13. Lebsanft HB, Scheller DKA, Heindl M, et al. Effect of continuous administration of rotigotine in a rat model of dyskinesia [abstract no. P297]. Mov Disord 2005; 20 Suppl. 10: S89 plus poster presented at the 9th International Congress of Parkinson's Disease and Movement Disorders; 2005 Mar 5-8; New Orleans (LA)
14. Scheller DKA, Heindl M, Schmidt W. Continuous administration of rotigotine does not induce dyskinesia in a rat model of PD [abstract no. P1262 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
15. Scheller DK, Smith L., Breidenbach A, et al. Effect of rotigotine on locomotor activity and disability scores in MPTP-treated common marmosets following subcutaneous administration [abstract no. P396]. Mov Disord 2004; 19 Suppl. 9: S145 plus poster presented at the 8th International Congress of Parkin-son's Disease and Movement Disorders; 2004 Jun 14-17; Rome
16. Schneider JS, McLaughlin WW, Roeltgen DP. Anti-Parkinson effects of the selective dopamine D-2 agonist N-0923 in hemi-Parkinsonian monkeys [abstract no. 1002P]. Neurology 1992 Apr; 42 (4 Suppl. 3): 443
17. Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation [abstract no. 250]. Ann Neurol 2004; 56 Suppl. 8: S54 plus poster presented at the 129th Annual Meeting of the American Neurological Association; 2004 Oct 3-6; Toronto (ON)
18. Stichel CC, Scheller DKA. Rotigotine prevents neurodegeneration in a mouse model of Parkinson's disease [abstract no. P1286 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
19. Timmerman W, Rusk IN, Tepper P, et al. The effects of enanti-omers of the dopamine agonist N-0437 on food consumption and yawning behaviour in rats. Eur J Pharmacol 1989 Dec 12; 174: 107-14
20. Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001 May; 16: 459-63
21. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003 Dec; 60 (12): 1721-8
22. Cawello W, Braun M, Horstmann R. Pharmacokinetics of trans-dermal rotigotine in subjects with impaired renal function [abstract no. 102]. J Clin Pharmacol 2005; 45 (9): 1091 plus poster presented at the 34th Annual Meeting of the American College of Clinical Pharmacology; 2005 Sep 11-13; Rockville (MD)
23. Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease [abstract no. P1245 plus poster]. 9th Con-gress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
24. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine [abstract no. 101]. J Clin Pharmacol 2005; 45 (9): 1091 plus poster presented at the 34th Annual Meeting of the American College of Clinical Pharmacology; 2005 Sep 11-13; Rockville (MD)
25. Braun M, Cawello W, Horstmann R. Lack of pharmacokinetic interaction between the dopamine agonist rotigotine and levodopa/carbidopa [abstract no. 4775 plus poster]. 16th International Congress on Parkinson's Disease and Related Disor-ders; 2005 June 5-9; Berlin
26. Watts RL, Wendt J, Nausieda PL, et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial [abstract no. P737]. Mov Disord 2004 Jun 14; 19 Suppl. 9: S258 plus poster presented at the 8th International Congress of Parkinson's Disease and Movement Disorders; 2004 Jun 14-17; Rome
27. Quinn N. for the SP 511 Investigators. Rotigotine transdermal delivery system (TDS) (SPM 962) - a multicenter, double-blind, randomized, placebo-controlled trial to asses the safety and efficacy of rotigotine TDS in patients with advanced Parkinson's disease [abstract no. P-TU-223]. Parkinsonism Relat Disord 2001; 7 Suppl. 1: S66 plus poster presented at the 14th International Congress on Parkinson's Disease; 2001 Jul 27- Aug 1; Helsinki
28. LeWitt PA, Chang F-L, Fazzini E, et al. Rotigotine transdermal system in treatment of patients with advanced-stage Parkin-son's disease [abstract no. SC115]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17-20; Athens
29. Babic T, Boroojerdi B, Randerath O, et al. Rotigotine CDS patch in advanced-stage, idiopathic Parkinson's disease: a parallel group, open-label, dose-escalation trial [abstract no. P05.095]. Neurology 2004 Apr 13; 62 (7 Suppl. 5): A399